Talus Bio

Emerging

Seattle AI drug discovery targeting transcription factors with MARMOT platform measuring 10,000 regulomes monthly; YC W21 $11.2M with FDA/EMA Phase I approval for MSD-001 cancer program.

Updated March 2026

Company Overview

About Talus Bio

Talus Bioscience is a Seattle-based AI-powered drug discovery company targeting transcription factors — the class of proteins historically considered "undruggable" that regulate gene expression and drive many cancers — using its proprietary MARMOT platform (MAssive Regulome Mapping Of Transcriptomes) to measure the binding activity of small molecules across 10,000+ regulomes monthly using live, unmodified human cells. Founded and backed by Y Combinator (W21) with $11.2 million in Seed+ funding raised in August 2024, Talus received FDA and EMA approval for Phase I human trials of its lead program MSD-001 in 2024 — advancing toward first-in-human studies for a transcription factor-targeted cancer therapy.

Business Model & Competitive Advantage

Talus' MARMOT platform addresses the fundamental challenge of targeting transcription factors: while transcription factors are implicated in 50%+ of human cancers, their protein surfaces lack the deep pockets that small molecule drugs typically bind to, making them resistant to conventional drug discovery approaches. MARMOT measures how potential drug molecules change the binding patterns of transcription factors across thousands of gene regulatory elements simultaneously — using native human cell systems rather than artificial model organisms — generating a functional readout of whether a molecule disrupts transcription factor activity in a biologically relevant context. This high-throughput functional screening approach identifies transcription factor-targeting compounds that would be missed by structure-based drug design.

Competitive Landscape 2025–2026

In 2025, Talus Bioscience competes in the targeted cancer therapy and AI drug discovery market with Black Diamond Therapeutics (NASDAQ: BDTX, cancer mutations), Blueprint Medicines (NASDAQ: BPMC, precision oncology), and AI drug discovery platforms (Recursion Pharmaceuticals, NASDAQ: RXRX) for transcription factor-targeted cancer program development. FDA and EMA Phase I approval for MSD-001 de-risks the most significant regulatory milestone for first-in-class transcription factor inhibitors and validates the MARMOT platform's output. Y Combinator's backing places Talus in the intersection of biotech and computational biology communities. The 2025 strategy focuses on advancing MSD-001 through Phase I safety trials, generating proof-of-concept data that enables partnership or out-licensing with larger pharmaceutical companies for Phase II/III development, and using MARMOT's platform capabilities for additional transcription factor targets.

Revenue
$11.2M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

Talus Bio is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Not So Random Others

Zeffy

Nonprofit Tech
B2bSaas

Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs

Oda Studio

Real Estate & Property Tech
B2bProptechAi PoweredSaas

Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal

Brisk

Consumer Food & Beverage
B2cManufacturingNorth AmericaFortune500

Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione

Altria

Consumer Goods
B2cManufacturingNorth AmericaPublicFortune500

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s

Cursor

Developer Tools & Platforms
B2bDeveloper ToolsSaasUnicorn

Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities dir

Kindful

Nonprofit Tech
B2bSaasSmb

Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid

Compare Talus Bio with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Talus Bio

Claim This Profile

Are you from Talus Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Talus Bio Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Talus Bio vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →